Trial Profile
A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2021
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PIANO
- 11 Aug 2021 Status changed from active, no longer recruiting to completed.
- 26 Feb 2021 Planned End Date changed from 1 Oct 2019 to 28 Feb 2021.
- 26 Feb 2021 Planned primary completion date changed from 1 Oct 2017 to 28 Feb 2021.